Sign up for News by Email
All Releases
View Summary Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015
May 13, 2015
PDF 12.2 KB
View Summary Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
May 12, 2015
PDF 18.9 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 UBS Global Healthcare Conference
May 11, 2015
PDF 8.0 KB
View Summary Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational Results
Apr 30, 2015
PDF 24.9 KB
View Summary Threshold Pharmaceuticals Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance to Conventional EGFR Tyrosine Kinase Inhibitors
Apr 22, 2015
PDF 18.0 KB
View Summary Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York City
Apr 16, 2015
PDF 15.6 KB
View Summary Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor
Mar 19, 2015
PDF 18.2 KB
View Summary Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial and Operational Results
Mar 3, 2015
PDF 59.8 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the 2015 Cowen Health Care Conference
Feb 24, 2015
PDF 9.6 KB
View Summary Threshold Pharmaceuticals Announces Pricing of $30 Million Offering of Common Stock and Warrants
Feb 12, 2015
PDF 11.1 KB
View Summary Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting
Dec 6, 2014
PDF 16.2 KB
View Summary Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Nov 25, 2014
PDF 9.5 KB
View Summary Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Nov 17, 2014
PDF 17.7 KB
View Summary Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Nov 11, 2014
PDF 15.4 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Nov 10, 2014
PDF 9.4 KB
View Summary Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Nov 6, 2014
PDF 11.5 KB
View Summary Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Nov 3, 2014
PDF 12.4 KB
View Summary Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Nov 3, 2014
PDF 23.7 KB
View Summary Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Nov 3, 2014
PDF 14.7 KB
View Summary Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
Sep 22, 2014
PDF 15.6 KB
Showing 1-20 of 266 Page: 1 2 3 4 5 ... 14  Next 20
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue